Divi’s Labs (DIVI), in addition to having a robust base business, is enhancing its product offerings in the generic API space – at least sixteen molecules are under various phases of development and ...
Divi's Laboratories, India's largest API (Active Pharmaceutical Ingredient) manufacturer, sits amid a changing landscape within the global pharmaceutical universe. The growth levers for Divi’s are ...
HYDERABAD, Feb 3 (Reuters) - India's Divi's Laboratories (DIVI.NS), opens new tab reported a better-than-expected quarterly profit on Monday, aided by strong performance of its business that focuses ...
The pharmaceutical industry has been traditionally slow in embracing new technologies, but Divi’s Laboratories is showing the way forward. Recently, this Hyderabad-based firm zeroed in on Juniper ...
Nov 7 (Reuters) - Indian drugmaker Divi's Laboratories (DIVI.NS), opens new tab reported second-quarter profit above analysts' estimates on Friday, helped by its business that focuses on customised ...
The FDA, which last month banned APIs coming from a Divi’s Laboratories plant in India, has followed that up with a warning letter that savages the facility for refusing to give inspectors records ...
Ashis Biswas, Head of Technical Research at CapitalVia Global Research highlights Fundamentals and Technical Analysis on Divi ...
Divi's Labs reported its Q1 results on August 3. Pharma company Divi's Laboratories announced plans to foray into peptide fragment molecules, advancing from the peptide building blocks it currently ...
Divi’s Laboratories came under pressure on Monday following a key negative development around a blockbuster cardiac drug. SEBI-registered analyst Prabhat Mittal said Divi’s made an intraday low of ...
Divi's Lab Share Price: Brokerage firm Citi seems positive on the shares of multinational pharmaceutical company- Divi's Laboratories Limited. During Friday's trade, Divi's Lab shares opened in green ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results